BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has submitted a Clinical Trial Application (CTA) to Health Canada for an NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory a

Emergex Signs Agreement with GEORGE MASON UNIVERSITY for Highly Pathogenic RNA Virus Studies

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2020 financial results on Wednesday, May 6, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2020. The conference call will be accessible by dialing toll-free (844) 701-1063

Focused on Creating ‘Cocktail’ of Therapeutic Peptides with both Antiviral and Cytokine Regulation Qualities to Modify Inflammatory Response Associated with COVID-19 Respiratory Damage Grant Funded by Partnership for Advanced Computing in Europe

Dr. Richard Whitley, a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery Joins Moleculin’s Science Advisory Board

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2020, at 4:30 p.m. EDT to discuss its financial results for the fiscal second quarter ended March 31, 2020. Conference Call and Webcast Details Investors may access a live audio webcast on the Company’s website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to partic

OPKO Health, Inc. provided an update on two abstracts regarding the global Phase 3 somatrogon pediatric trial evaluating somatrogon dosed once weekly in pre-pubertal children with growth hormone deficiency.

Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company, announced that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon Barbari for election as a class III director to replace Abhijeet Lele, a member of the company’s board of directors and the board’s Lead Independent Director, who will not stand for re-election and cease to be a director on June 9, 2020, the date of the company’s Annual Meeting of Stockholders. In addit

CorMedix Inc. announced that it has completed the previously announced sale of $5.5 million of the total $6.0 million of its available tax benefits to an unrelated, profitable New Jersey corporation through the New Jersey Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2019.